Development of psychedelic medicine to treat mental health-related medical conditions such as depression, anxiety, addiction, and trauma-related stress disorder.
We are developing industrial-scale production of pharmaceutical-grade psychedelic compounds, including psilocybin and mescaline. Our hope is to support further research into their potential as treatment options for mental health-related medical conditions.
We are focused on applying XPhyto’s drug formulation expertise and Vektor’s proven drug delivery platforms to emerging APIs. This has the potential to create standardized drug formulations with safe and precise dosing for clinical study and therapeutic use.